Related Experiment Video
Updated: May 25, 2025
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.6K
Clinical Progress of Fruquintinib in Colorectal Cancer: An Overview
Yejie Xie1, Shu Tang2, Ziheng Qin1
1The Second Clinical School of Wuhan University, Wuhan 430071, China.
Pharmaceuticals (Basel, Switzerland)
|February 26, 2025
Summary
Fruquintinib, a VEGFR inhibitor, shows significant efficacy in treating metastatic colorectal cancer (mCRC). Clinical trials establish it as a standard third-line treatment, improving survival for refractory mCRC patients.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Colorectal cancer (CRC) presents high global morbidity and mortality.
- Advanced and metastatic CRC (mCRC) show limited response to conventional therapies.
- Fruquintinib is a novel, selective vascular endothelial growth factor receptor (VEGFR) inhibitor.
Purpose of the Study:
- To review fruquintinib's pharmacology, pharmacokinetics, and adverse events in CRC.
- To update on clinical trials investigating fruquintinib for colorectal cancer.
- To provide insights into fruquintinib's role in comprehensive CRC treatment.
Main Methods:
- Comprehensive literature search of PubMed.
- Consultation of clinical trials via ClinicalTrials.gov and ChiCTR.
- Systematic review of existing knowledge and trial data.
Main Results:
- Fruquintinib demonstrates significant efficacy and tolerance in mCRC patients.
- FRESCO and FRESCO-2 trials confirm prolonged progression-free and overall survival in refractory mCRC.
- Fruquintinib is established as a standard third-line treatment for mCRC.
Conclusions:
- Fruquintinib is an effective treatment for refractory metastatic colorectal cancer.
- Combination therapies with fruquintinib show potential for enhanced efficacy.
- Further research is warranted to explore fruquintinib's full therapeutic potential in CRC.
Related Concept Videos
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K